R, S., R, B., A, A., MB, M., A, G., N, M., . . . KM, L. (2024). Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: A UK real-world experience. Blood advances, 8(4), 878. https://doi.org/10.1182/bloodadvances.2023011305
Chicago Style (17th ed.) CitationR, Shotton, et al. "Safety of Bendamustine for the Treatment of Indolent Non-Hodgkin Lymphoma: A UK Real-world Experience." Blood Advances 8, no. 4 (2024): 878. https://doi.org/10.1182/bloodadvances.2023011305.
MLA (9th ed.) CitationR, Shotton, et al. "Safety of Bendamustine for the Treatment of Indolent Non-Hodgkin Lymphoma: A UK Real-world Experience." Blood Advances, vol. 8, no. 4, 2024, p. 878, https://doi.org/10.1182/bloodadvances.2023011305.
Warning: These citations may not always be 100% accurate.
